Reportstack is one of the largest online libraries of market research publications. We are the fastest growing and most preferred provider of business intelligence in the market today. We partner with the world's top publishers and research houses to bring to you expert analysis, accurate data and market information along with the best customer support and user experience. For more details, please visit www.reportstack.com
Thursday, 18 May 2017
Growth Prospects of the PD-1 and PD-L1 Inhibitors, 2017
PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 is a new market research publication announced by Reportstack. This report predicts that PD-1 and PD-L1 inhibitors are among the highly growing fields in biopharmaceutical industry. Most of these immunotherapeutic are being used in Oncology. There are 51 active drugs in the pipeline. Companies have also gone in collaboration with different partners like Bristol, Merck, AstraZeneca and Roche for evaluating their drugs in combination with Immune Checkpoint Inhibitors (PD-1/PD-L1). There are total 40 companies which are active in the development of different drugs targeting PD-1 and PD-L1.
Out of 51 active drugs, 45 drugs are in Monotherapy and 6 drugs are in the combination therapy. Out of 45 Monotherapy drugs, 2 are in Filed stage and 5 drugs are in phase III, 1 drug are in Phase II, 13 drugs are in Phase I, 20 drugs are in Pre-Clinical and 3 drugs are in Discovery phase and 1 in Unknown stage. Out of 6 combination therapy drugs, 1 is in Phase II, 3 are in Pre-Clinical stage of development and 2 are in Discovery stage.
Future competitive landscape of PD-1 and PD-L1 inhibitors is estimated to be very strong. There are 3 marketed products of PD-1 and PD-L1 inhibitors. Treatment options such as surgery, chemotherapy, radiation therapy, and many others are able to fulfill the current unmet need to an extent. With 7 drugs in the Phase III pipeline of the PD-1 and PD-L1 inhibitors, the market looks promising in coming years as well.
PD-1 and PD-L-1 inhibitors are showing greater efficacy as immune-therapeutic drugs but with the immune system unchecked, there is the possibility that immune cells attack other parts of the body, causing serious problems in the intestines, liver, nerves, eyes, or other organs. Although Preliminary data suggests that PD-1/PD-L1 immunotherapies provide faster and more frequent responses.